Konsultasi Daring dengan Dokter Onkologi Dokter Terbaik di Israel - TOP-32 dokter

Dokter adalah seorang ahli onkologi yang sangat dihormati dengan pengalaman luas dalam berbagai perawatan kanker. Dia telah berkontribusi secara signifikan dalam penelitian klinis, terutama dalam memahami dan meningkatkan sikap pasien terhadap uji klinis. Fokus klinisnya mencakup prosedur lanjutan seperti Kemoterapi Intraperitoneal Hipertermik (HIPEC), terapi SIRT, dan imunoterapi dengan Keytruda. Dokter juga melakukan operasi kompleks termasuk operasi Whipple, reseksi hati, dan operasi kanker pankreas, menunjukkan pendekatan komprehensif terhadap perawatan onkologi.<\/p>

Dr. Ofer Merimsly adalah dokter terbaik untuk kanker sarkoma, limfoma, dan paru-paru di Israel dan dunia. Juga mengkhususkan diri dalam perawatan bedah Whipple untuk pasien dengan kanker pankreas. Kepala Pusat Nasional untuk sarkoma tulang dan jaringan lunak di Tel Aviv Medical Center Sourasky (Ichilov).

Spesialisasi:

• Perawatan semua jenis kanker paru-paru dan organ toraks
• Perawatan semua jenis sarkoma tulang dan jaringan lunak
• Perawatan tumor stroma pada saluran pencernaan

Pendidikan dan spesialisasi:

• Pendidikan kedokteran tinggi, lulus dari Fakultas Kedokteran Universitas Ibrani Yerusalem, Israel
• Residensi dalam Onkologi Umum dan Radioterapi
• Pelatihan di bidang radioterapi dan brakiterapi di New York Hospital, USA
• Kursus penyegaran khusus untuk perawatan tumor rangka dan jaringan lunak, Paris, Prancis

Keanggotaan:

• Presiden Perhimpunan Onkolog dan Radioterapist Israel
• Masyarakat Ilmiah Kanker Amerika
• Organisasi medis ilmiah Eropa
• Perhimpunan Onkologi Sistem Muskuloskeletal Eropa
• Perhimpunan Internasional untuk perawatan tumor jaringan ikat

Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.

He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.

He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.

His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.

Dr. Arnon Nagler is an internationally recognized hematologist and bone marrow transplant expert. He is a Professor of Medicine at Tel Aviv University. He is Director Emeritus of Hematology & Bone Marrow Transplantation and the Cord Blood Bank at Sheba Medical Center. He earned his M.D. from the Hebrew University–Hadassah and an M.Sc. in hematopoiesis from Tel Aviv University. He completed postdoctoral training at Stanford. He is board certified in internal medicine and hematology.

He has more than 35 years of experience. He pioneered reduced‑intensity allogeneic transplant protocols for malignant and non‑malignant diseases. He founded Israel’s first public cord blood bank. He performed the country’s first cord blood transplants.

He has held international leadership roles. He served as Chair and Co‑Chair of the ALWP of the EBMT. He was a vice‑chair and long‑term member of EBMT committees. He served on the board of NetCord/EuroCord and as treasurer. He is a frequent invited speaker. He has published widely in journals such as Blood and Leukemia. He has led major clinical trials as a principal investigator and held editorial roles. He has received multiple awards for innovation and clinical excellence.

Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.

She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.

She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.

She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.

Prof. Zvi Cohen is Director of the Neurosurgery Department and the Neuro-Oncology Unit at Sheba Medical Center. He is a neurosurgeon and neuro-oncology expert. He was included in Forbes Israel’s Best Doctors 2025. He leads clinical research on drug therapies for malignant brain tumors. He also founded Sheba’s brain tumor tissue bank.

He is board-certified in neurosurgery. He trained at Tel Aviv University. He completed fellowships in neuroradiology at Beth Israel and in neurosurgical oncology at MD Anderson. His practice covers complex brain, pituitary, spine, and spinal cord tumors. He has expertise in stereotactic biopsies, image-guided resections, intraoperative MRI, navigation systems, and radiosurgery. He is a member of the Society for Neuro-Oncology and the Israeli Association of Neurological Surgeons.

Professor Dov Zippel is a general surgeon and surgical oncologist. He specializes in breast disease and melanoma. He leads the Meirav Breast Center at Sheba Medical Center. He also serves at the Ella Lemelbaum Institute for Immuno-Oncology. In 2025, Forbes Israel named him to its Best Doctors list.

Expertise: advanced care for benign and malignant breast tumors. Minimally invasive and breast-conserving surgery. Surgical treatment of melanoma and other skin cancers.

Accreditations: MD, Tel Aviv University. Residency in general surgery, Sheba Medical Center. Fellowship in surgical oncology, University of Calgary. Board-certified in general surgery and surgical oncology. Research includes intact breast lesion excision and perioperative BRAF inhibitors for stage III melanoma.

Dr. Einat Shacham‑Shmueli is a senior medical oncologist at the Gastrointestinal Clinic, Cancer Center, Sheba Medical Center. She treats cancers of the colon, stomach, and pancreas. She also manages metastatic disease. She uses precision diagnostics and biomarkers, systemic therapies, and radiotherapy. Care is provided within a multidisciplinary team.

She has authored more than 25 peer‑reviewed papers on GI oncology, tumor biology, and new treatments. Her work includes studies on stenting for malignant colonic obstruction. She serves as an investigator in international programs, including the NCI, the Radiation Therapy Oncology Group, and the Cancer Therapy Evaluation Program.

Education: MD, Tel Aviv University. Oncology residency, Tel Aviv Sourasky Medical Center. Advanced training in GI oncology, UCSF. Accreditations: Board certified in Oncology and Gastroenterology. Member, Israel Society of Oncology and Radiotherapy.

Prof. Amit Tirosh is a senior endocrinologist and Head of the Neuroendocrine Tumors Service at Sheba Medical Center. He specializes in neuroendocrine tumors (NETs).

His work centers on hereditary NET syndromes. He is affiliated with the NIH in MEN1 research. He serves on an international VHL expert panel and helped write VHL management guidelines. He is the primary contact at Sheba’s multidisciplinary VHL clinic.

He leads the Endocrine Oncology Bioinformatics Lab. He collaborates with international teams, including the Weizmann Institute. He provides advanced NET care, including PRRT.

He earned his MD from the Hebrew University–Hadassah. He completed a residency at Assaf HaRofeh, an endocrinology fellowship at Rabin, and training at the NIH. He is board-certified in Endocrinology. He is a member of the Israeli Society of Endocrinology, the Endocrine Society, and the European Neuroendocrine Tumor Society. He has authored over 40 peer-reviewed papers, including in JAMA, Gastroenterology, and Radiology.

Dr. Almog Ben-Yaacov is an Attending Surgeon in the Department of General and Oncological Surgery (Surgery C) at Sheba Medical Center. He specializes in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). His clinical focus includes gastric cancer, sarcoma, and complex colorectal malignancies. Since 2018, he has performed more than 200 HIPEC procedures.

MD, Semmelweis University, 2006, with honors. Training in cardiothoracic surgery at Sheba Medical Center. Residency in general surgery at Montefiore (Albert Einstein) and at Rabin (Beilinson). Board-certified in General Surgery and in Surgical Oncology.

Advanced training includes ESSO-certified HIPEC in Hamburg. Microwave liver ablation in Reims. NanoKnife at King’s College London. Advanced surgical oncology at Memorial Sloan Kettering (2019). His publications cover CRS+HIPEC outcomes and Hartmann’s reversal.

Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.

He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.

He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.

Profesor Ari Rafael — direktur layanan Onkologi Translasional dan peneliti di departemen penelitian klinis kanker di Pusat Medis Suraski (Ichilov, Tel Aviv). Pasien menghargai pendekatannya yang individual dan perhatian terhadap kebutuhan setiap individu.

Kualifikasi dan nilai bagi pasien:

• Memimpin rumah sakit onkologi siang hari dan mengarahkan proyek-proyek kedokteran genom nasional. Hal ini memastikan akses ke penelitian terkini.

• Bekerja sebagai penyelidik sub-utama dan penyelidik utama dalam banyak uji klinis fase I–III, termasuk suntikan intratumoral mRNA dan obat-obatan virus. Pasien mendapatkan kesempatan untuk berpartisipasi dalam metode pengobatan inovatif.

• Memiliki pengalaman internasional di AS dan Inggris — menjamin penerapan standar dunia dan protokol canggih.

• Anggota organisasi internasional (ESMO, IASLC, ISLB, ISCORT, Asosiasi Medis Israel). Menggunakan standar pengobatan modern dan berpartisipasi dalam penelitian global.

• Secara rutin meningkatkan kualifikasi dan mengikuti pelatihan sesuai standar praktik klinis internasional, termasuk ICH GCP R2, Panduan MOH Israel, serta kursus terbaru tentang persetujuan yang diinformasikan, penanganan efek samping, dan keselamatan pasien.

Pasien menghargai Profesor Rafael atas pilihan rencana pengobatan yang tepat, penerapan inovasi, dan perhatian yang mendetail, yang memberikan rasa percaya dan aman pada setiap tahap terapi.

Dokter lulus dari Universitas Grodno, Belarus, dan memperoleh lisensi medis di Israel pada tahun 2000. Mengkhususkan diri dalam bidang penyakit dalam dan onkologi, dokter menyelesaikan magang di Departemen Penyakit Dalam ke-10 dan Onkologi di Pusat Medis Tel Aviv, Ichilov. Sejak 2015, dokter telah menjabat sebagai direktur rawat inap onkologi di pusat yang sama.<\/p>

Dengan pengalaman luas sebagai peneliti utama dan sekunder, dokter telah berpartisipasi dalam studi klinis fase pertama, kedua, dan ketiga dalam onkologi, memberikan kontribusi yang signifikan di bidang ini.<\/p>

Dokter adalah spesialis berpengalaman dalam Transplantasi Sumsum Tulang, setelah lulus dari Sekolah Kedokteran Universitas Ibrani pada tahun 1999. Setelah itu, dokter mengambil spesialisasi dalam bidang penyakit dalam di Pusat Medis Hadassah. Dokter kemudian bergabung dengan departemen Transplantasi Sumsum Tulang di Hadassah sebagai dokter senior, memberikan kontribusi keahlian yang signifikan di bidang ini.<\/p>

Dokter adalah pakar terkemuka dalam hematologi dan onkologi pediatrik, yang mengkhususkan diri dalam gangguan darah dan kanker tulang (sarkoma) pada anak-anak. Saat ini, dokter menjabat sebagai direktur departemen hematologi onkologi anak di Sourasky Medical Center di Tel Aviv dan merupakan dokter anak senior di Rumah Sakit Anak Dana. Dokter mengoordinasikan perawatan untuk kanker tulang dan sarkoma jaringan lunak, mengelola gangguan pembekuan darah, dan mengawasi hematologi pada bayi prematur. Dokter adalah anggota Asosiasi Hemato-Onkologi Pediatrik Israel (ISPHO).

Dokter lulus dari Universitas Ben-Gurion dan mengkhususkan diri dalam kedokteran anak di Kaplan Medical Center, dengan spesialisasi lebih lanjut dalam hematologi dan onkologi pediatrik di Schneider Children's Medical Center. Pelatihan tambahan diselesaikan dalam onkologi tulang dan jaringan lunak di Institut Ortopedi Rizzoli di Italia.

Dokter adalah spesialis terkemuka di departemen terapi nuklir di Klinik Ichilov, berfokus pada perawatan inovatif untuk tumor neuroendokrin menggunakan terapi radionuklida dengan Lutetium-177. Metode ini, tersedia di Israel, Jerman, dan Swedia, secara selektif menghancurkan sel kanker sambil menyelamatkan jaringan sehat, menghindari efek samping parah dari kemoterapi tradisional.<\/p>

Dengan gelar medis dari Vitebsk, Belarus, dan spesialisasi dalam onkologi dan terapi radiasi dari Rumah Sakit Universitas Hadassah, dokter memiliki pengalaman luas dalam onkologi, terutama dalam terapi radiasi untuk anak-anak, tumor gastrointestinal, kepala, leher, dan kulit.<\/p>

Dokter adalah seorang Onkolog Medis dan Radioterapis dengan pengalaman 33 tahun, yang mengkhususkan diri dalam Onkologi dan Radioterapi. Mereka lulus dari Rumah Sakit Universitas Hadassah di Yerusalem, Israel, dan memiliki kualifikasi dalam Onkologi dan Radioterapi.<\/p>

Saat ini menjabat sebagai Kepala Pusat Kanker Gastrointestinal, dokter juga merupakan Dokter Senior di Departemen Onkologi di Rumah Sakit Universitas Hadassah. Mereka telah menyelesaikan ujian dewan dalam Onkologi dan Radioterapi, dan merupakan anggota dari beberapa masyarakat profesional, termasuk Masyarakat Onkologi Klinis Israel dan Asosiasi Kanker Israel.<\/p>

Dr. Boaz Liberman, MD, is an orthopedic oncologist and sarcoma surgeon for adults and children. He directs the Orthopedic Oncology Unit and serves as Vice Head of Orthopedic Surgery at Sheba Medical Center. His focus is limb-sparing cancer surgery with functional reconstruction. He performs complex joint reconstruction, revision arthroplasty, MRgFUS, and reconstruction after bone metastases.

Education and training: MD, Tel Aviv University. Orthopedic surgery residency, Sheba Medical Center. Fellowships in Adult Reconstruction at Mount Sinai Hospital, Toronto, and in Orthopedic Oncology at Mount Sinai Hospital and Princess Margaret Cancer Centre. He is board-certified in Orthopedic Surgery and in Orthopedic Oncology Surgery. He is a Clinical Instructor at Tel Aviv University. Memberships include the Israel Medical Association, Israel Orthopedic Association, AATB, and EATB. He also serves on national advisory committees. His research covers bone and soft tissue sarcomas, serum markers, imaging-guided therapies, MRI arthrography, and the biomechanics of bone treated with MRgFUS.